MedTrace Logo

Coproporphyrine Isomers and Methotrexate Elimination

NCT00822432 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 85

Last updated 2012-07-31

No results posted yet for this study

Summary

High dose methotrexate (MTX) is responsible of severe toxicity in patients in whom elimination from plasma is delayed. Factors responsible for MTX accumulation are partly known but some patients still experience toxicity despite adequate measures being taken. Our hypothesis is that renal tubular secretion may be impaired in these patients. This study aims at evaluating the performance of the UCP ratio (urinary ratio of coproporphyrins), a putative biomarker of tubular secretion, in predicting delayed MTX elimination.

Conditions

  • Central Nervous System Neoplasms
  • Lymphoma, Large B-Cell, Diffuse
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  • Burkitt Lymphoma

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Chantal Le Guellec, PharmD, PhD · CHRU of Tours

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00822432 on ClinicalTrials.gov